The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Optimizing patient selection for targeted therapies in G/GEJ cancer
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, highlights the importance of biomarkers in selecting patients for dual trastuzumab and pembrolizumab therapy in gastric cancer or gastroesophageal junction (G/GEJ) cancer. Targeted patient selection could enable de-escalation of chemotherapy, minimizing side effects while maintaining efficacy. With the rapidly evolving first-line treatment landscape, agents like claudin 18.2 and FGFR monoclonal antibodies are emerging. interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
